Evidence map›Paper›PMID 42776425›Full record

ArticleMolecular diversity2026

Discovery of potent and selective MAO-B inhibitors from a morpholine-substituted chalcone library for neurodegenerative disorders.

Asmar Taghiyeva, Jaeyeop Lim, Abanish Biswas, Subodh Mondal, Ritika Uppal Mukherjee, Vinay N Basavanakatti, Nilüfer Bayrak, Venkatesan Jayaprakash, Man-Jeong Paik, Hoon Kim and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Asmar Taghiyeva *Department of Chemistry, Faculty of Science, Istanbul University, 34134, Fatih, Istanbul, Turkey.
Jaeyeop Lim *Department of Pharmacy, College of Pharmacy, Sunchon National University, Suncheon, 57922, Republic of Korea.
Abanish BiswasDepartment of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, 835215, India.
Subodh MondalEurofins Advinus Biopharma Services Private Limited, Bangalore, India.
Ritika Uppal MukherjeeEurofins Advinus Biopharma Services Private Limited, Bangalore, India.
Vinay N BasavanakattiAdgyl Lifesciences Private Limited, Bengaluru, India.
Nilüfer BayrakDepartment of Chemistry, Faculty of Science, Istanbul University, 34134, Fatih, Istanbul, Turkey.
Venkatesan JayaprakashDepartment of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, 835215, India. venkatesanj@bitmesra.ac.in.
Man-Jeong PaikDepartment of Pharmacy, College of Pharmacy, Sunchon National University, Suncheon, 57922, Republic of Korea. paik815@sunchon.ac.kr.
Hoon KimDepartment of Pharmacy, College of Pharmacy, Sunchon National University, Suncheon, 57922, Republic of Korea. hoon@sunchon.ac.kr.
Amaç Fatih TuYuNDepartment of Chemistry, Faculty of Science, Istanbul University, 34134, Fatih, Istanbul, Turkey. aftuyun@gmail.com.

Funding

National Research Foundation of Korea (NRF) grant funded by the Korean Government RS-2024-00347522the Scientific Research Projects Coordination Unit of Istanbul University FDK-2024-40841
6 · The paper itself

Abstract

A series of targeted chalcones (TCs) was designed and synthesised using a microwave-assisted synthetic method to introduce diverse substituents at different positions on the phenyl ring. The structures of all nineteen TC analogues were confirmed by NMR, FTIR, and HRMS. In vitro tests against acetyl- and butyrylcholinesterases (AChE and BuChE), β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1), and monoamine oxidases (MAO-A and MAO-B) showed that MAO-B was the most potent and selective. Among them, TC12 was the strongest inhibitor (IC

Indexed as

ChalconesCholinesteraseKinetic studyMolecular dockingMonoamine oxidaseParkinson’s diseaseReversibility

Identifiers

PMID42776425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.